These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 17222644)

  • 1. A preliminary study of JM-27: a serum marker that can specifically identify men with symptomatic benign prostatic hyperplasia.
    Cannon GW; Mullins C; Lucia MS; Hayward SW; Lin V; Liu BC; Slawin K; Rubin MA; Getzenberg RH
    J Urol; 2007 Feb; 177(2):610-4; discussion 614. PubMed ID: 17222644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum Mac-2BP does not distinguish men with high grade, large volume prostate cancer from men with benign prostatic hyperplasia.
    Peehl DM; Chen Z; Nolley R
    Prostate; 2011 Jan; 71(1):26-31. PubMed ID: 20583127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of benign prostatic hyperplasia disease.
    Marks LS; Roehrborn CG; Andriole GL
    J Urol; 2006 Oct; 176(4 Pt 1):1299-306. PubMed ID: 16952616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody array profiling reveals serum TSP-1 as a marker to distinguish benign from malignant prostatic disease.
    Shafer MW; Mangold L; Partin AW; Haab BB
    Prostate; 2007 Feb; 67(3):255-67. PubMed ID: 17192876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum early prostate cancer antigen (EPCA) as a significant predictor of incidental prostate cancer in patients undergoing transurethral resection of the prostate for benign prostatic hyperplasia.
    Zhao Z; Zeng G; Zhong W
    Prostate; 2010 Dec; 70(16):1788-98. PubMed ID: 20583137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer.
    Tahir SA; Ren C; Timme TL; Gdor Y; Hoogeveen R; Morrisett JD; Frolov A; Ayala G; Wheeler TM; Thompson TC
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3653-9. PubMed ID: 14506154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
    Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
    J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple marker evaluation in human prostate cancer with the use of tissue-specific antigens.
    Kuriyama M; Wang MC; Lee CL; Killian CS; Papsidero LD; Inaji H; Loor RM; Lin MF; Nishiura T; Slack NH; Murphy GP; Chu TM
    J Natl Cancer Inst; 1982 Jan; 68(1):99-105. PubMed ID: 6172628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antibody response to Propionibacterium acnes is an independent predictor of serum prostate-specific antigen levels in biopsy-negative men.
    Shannon BA; Cohen RJ; Garrett KL
    BJU Int; 2008 Feb; 101(4):429-35. PubMed ID: 17850358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum hepatocyte growth factor activator (HGFA) in benign prostatic hyperplasia and prostate cancer.
    Nagakawa O; Yamagishi T; Fujiuchi Y; Junicho A; Akashi T; Nagaike K; Fuse H
    Eur Urol; 2005 Oct; 48(4):686-90. PubMed ID: 16005141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum inhibin--not a cause of low testosterone levels in hypogonadal prostate cancer?
    Lackner JE; Maerk I; Koller A; Bieglmayer C; Marberger M; Kratzik C; Schatzl G
    Urology; 2008 Nov; 72(5):1121-4. PubMed ID: 18407338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems.
    Parsons JK
    J Urol; 2007 Aug; 178(2):395-401. PubMed ID: 17561143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.
    Dobosy JR; Roberts JL; Fu VX; Jarrard DF
    J Urol; 2007 Mar; 177(3):822-31. PubMed ID: 17296351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of prostate cancer with a blood-based assay for early prostate cancer antigen.
    Paul B; Dhir R; Landsittel D; Hitchens MR; Getzenberg RH
    Cancer Res; 2005 May; 65(10):4097-100. PubMed ID: 15899799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.
    Antunes AA; Leite KR; Sousa-Canavez JM; Camara-Lopes LH; Srougi M
    J Urol; 2009 Feb; 181(2):594-600. PubMed ID: 19084862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum resistin levels in benign prostate hyperplasia and non-metastatic prostate cancer: possible role in cancer progression.
    Housa D; Vernerova Z; Heracek J; Cechak P; Rosova B; Kuncova J; Haluzik M
    Neoplasma; 2008; 55(5):442-6. PubMed ID: 18665756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of plasma interleukin-8 concentration in patients with prostate cancer and benign prostate hyperplasia.
    Dehghani M; Mostafavi-Pour Z; Lotfi M; Shakeri S
    Iran J Immunol; 2009 Jun; 6(2):92-8. PubMed ID: 19561378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.
    Marks LS; Fradet Y; Deras IL; Blase A; Mathis J; Aubin SM; Cancio AT; Desaulniers M; Ellis WJ; Rittenhouse H; Groskopf J
    Urology; 2007 Mar; 69(3):532-5. PubMed ID: 17382159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.
    Kristal AR; Arnold KB; Schenk JM; Neuhouser ML; Weiss N; Goodman P; Antvelink CM; Penson DF; Thompson IM
    J Urol; 2007 Apr; 177(4):1395-400; quiz 1591. PubMed ID: 17382740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiprostasome antibody titres in benign and malignant prostate disease.
    Minelli A; Ronquist G; Carlsson L; Mearini E; Nilsson O; Larsson A
    Anticancer Res; 2005; 25(6C):4399-402. PubMed ID: 16334115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.